Screener
Aquestive Therapeutics, Inc. AQST Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:08 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000030
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 175,179 | 194,087 |
| Contingencies (Note 20) | ||
| Stockholders’ deficit: | ||
| Common stock, $0.001 par value. Authorized 250,000,000 shares; 124,284,542 and 122,044,299 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 124 | 122 |
| Additional paid-in capital | 420,877 | 413,214 |
| Accumulated deficit | (455,055) | (446,998) |
| Total stockholders’ deficit | (34,054) | (33,662) |
| Total liabilities and stockholders’ deficit | $141,125 | $160,425 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s total equity?
- Aquestive Therapeutics, Inc. (AQST) reported total equity of -$34.05M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s total equity changed year-over-year?
- Aquestive Therapeutics, Inc.'s total equity increased by 44.1% year-over-year, from -$60.93M to -$34.05M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Aquestive Therapeutics, Inc.'s total equity has grown at a -7.0% compound annual growth rate (CAGR), from -$48.5M to -$33.66M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Aquestive Therapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude